← Human Trials & Peer-Reviewed Studies
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
Plain-language guide to PMID 24980665 (2014): double-blind randomized controlled trial study of Glucagon and Dulaglutide, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 24980665
- Journal
- Hypertension (Dallas, Tex. : 1979)
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Ferdinand KC et al. (10 authors)
- DOI
- 10.1161/HYPERTENSIONAHA.114.03062
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glucagon and Dulaglutide in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.
The effects of dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, on BP and heart rate were investigated using ambulatory BP monitoring.
Ambulatory BP monitoring was performed at baseline and at 4, 16, and 26 weeks.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.
The methods mention a period of 26 weeks.
What Was Measured
The primary end point was change from baseline to week 16 in mean 24-hour SBP, a tree gatekeeping strategy compared the effects of dulaglutide to placebo.
Topics PubMed links to this paper include Blood Pressure, Blood Pressure Monitoring, Ambulatory, Diabetes Mellitus, Type 2, Diarrhea, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides and Glycated Hemoglobin.
Author keywords: dulaglutide, heart rate, hypertension and type 2 diabetes mellitus.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Dulaglutide in people with low blood pressure and orthostatic hypotension over 26 weeks.
The publication is from 2014 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.
More context: the Glucagon compound page and the Dulaglutide compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compounds
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Dulaglutide: A once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.
Related Pages
- Low blood pressure and orthostatic hypotension research
- Glucagon in the library
- Dulaglutide in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.